# New Drug Review and Recommended PA Criteria

**DISCLAIMER ALERT**: ^^The Ohio UPDL trumps all recommended criteria presented on this page^^. These are suggested recommended PA criteria for newly released medications.  Once ODM evaluates and determines their own specific criteria, that will take precedent.

## Roctavian (valoctocogene roxaparvovec-rvox) 7/25/23

[Roctavian (valoctocogene roxaparvovec-rvox).pdf](https://mygainwell.sharepoint.com.mcas.ms/teams/ClinicalLibrary/PublicClinicalDocuments/Forms/AllItems.aspx?id=%2Fteams%2FClinicalLibrary%2FPublicClinicalDocuments%2FRoctavian%20%28valoctocogene%20roxaparvovec%2Drvox%29%2Epdf&parent=%2Fteams%2FClinicalLibrary%2FPublicClinicalDocuments){:target="_blank" rel="noopener"}

| **WAC Price per Unit and Cost per Year/Treatment** |
| --------|
| One vial (16 x 1013 vg/ 8mL) = $90,625. For a 70 kg patient, the one-time treatment price would be $2,378,906.25 |


| **Suggested Prior Authorization/Utilization Management Criteria** |
| --------|
| ***Approval length***: one-time approval |
| ***Indication***: Treatment of adults with severe hemophilia A (congenital factor VIII deficiency with factor VIII activity < 1 IU/dL) without pre-existing antibodies to adeno-associated virus serotype 5 detected by an FDA-approved test |
| ***Initial Therapy***: <li>Patient age ≥ 18 years1 AND</li><li>Male gender assigned at birth2 AND</li><li>Diagnosis of severe congenital hemophilia A (Factor VIII activity level ≤1 IU/dL) AND</li><li>Documentation of no detectable antibodies to AAV5 AND</li><li>No evidence of liver dysfunction, fibrosis or HIV AND</li><li>Documentation of prophylaxis with Factor VIII within the previous year</li> |
| ***Additional Considerations***: <li>Perform regular ALT testing to monitor for elevations. Elevated liver enzymes, especially elevated ALT, may indicate immune-mediated hepatotoxicity and may be associated with decline in factor VIII activity</li> | 

## Elevidys (delandistrogene moxeparvovec-rokl) 7/11/23

[***Carve Out Medication Process]([https://special-spoon-f542dccd.pages.github.io/Pharmacist%20Reference%20Guide/Clinical%20and%20PA%20Notes/newdrugreview/](https://special-spoon-f542dccd.pages.github.io/Clinical%20and%20Technical%20Reference%20Guide/PA%20-%20Standard%20of%20Work/carved_out_medications/?h=carve)https://special-spoon-f542dccd.pages.github.io/Clinical%20and%20Technical%20Reference%20Guide/PA%20-%20Standard%20of%20Work/carved_out_medications/?h=carve)

[Elevidys (delandistrogene moxeparvovec-rokl).pdf](https://mygainwell.sharepoint.com.mcas.ms/teams/ClinicalLibrary/PublicClinicalDocuments/Forms/AllItems.aspx?id=%2Fteams%2FClinicalLibrary%2FPublicClinicalDocuments%2FElevidys%20%28delandistrogene%20moxeparvovec%2Drokl%29%2Epdf&parent=%2Fteams%2FClinicalLibrary%2FPublicClinicalDocuments){:target="_blank" rel="noopener"}

| **WAC Price per Unit and Cost per Year/Treatment** |
| --------|
| $3.2 million for one-time treatment |


| ~~**Suggested Prior Authorization/Utilization Management Criteria**~~ |
| --------|
| ~~***Approval length***: one-time treatment~~ |
| ~~***Indication***: Treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene.~~  |
| ~~***Initial Therapy***: <li>Prescribed by or in consultation with a neurologist or DMD specialist AND</li><li>Age either 4 or 5 years AND</li><li>Patient has male gender assigned at birth AND</li><li>Established clinical diagnosis of DMD and documented dystrophin gene mutation of DMD phenotype (documentation of a frameshift mutation contained between exons 18 and 58 (inclusive)) AND</li><li>Baseline anti-AAVrh74 antibody titers <1:400 AND</li><li>DNo evidence of any deletion in exon 8 and/or exon 9 in the DMD gene</li>~~ |

## Vyjuvek (beremagene geperpavec-svdt) 6/27/23

[Vyjuvek (beremagene geperpavec-svdt).pdf](https://mygainwell.sharepoint.com.mcas.ms/teams/ClinicalLibrary/PublicClinicalDocuments/Forms/AllItems.aspx?id=%2Fteams%2FClinicalLibrary%2FPublicClinicalDocuments%2FVyjuvek%20%28beremagene%20geperpavec%2Dsvdt%29%2Epdf&parent=%2Fteams%2FClinicalLibrary%2FPublicClinicalDocuments){:target="_blank" rel="noopener"}

| **WAC Price per Unit and Cost per Year/Treatment** |
| --------|
| Vyjuvek will be available at a wholesale acquisition cost (WAC) of $24,250 per vial. Krystal Biotech anticipates the average patient will utilize 26 vials per year ($630,500 annually) OR if a patient receives treatment weekly for 12 months, annual WAC price would be double ($1.3 million). |

| **Suggested Prior Authorization/Utilization Management Criteria** |
| --------|
| ***Approval length***: Initial- 6 months; Continuation of therapy- 1 year |
| ***Indication***: Treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene. |
| ***Qty Limit***: 26 vials/6 months |
| ***Initial Therapy***: <li>Prescribed by or in consultation with a dermatologist specializing in EB care</li><li>Patient aged 6 months or older</li><li>Diagnosis of DEB (either DDEB or RDEB) with documentation of mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene</li> |
| ***Continuation of Therapy***: <li> Provider documentation of continued benefit as evidence by: Improved wound healing defined as complete (100%) wound closure confirmed and documented in chart</li> |

## Inpefa (sotagliflozin) 6/12/23

[Inpefa (sotagliflozin).pdf](https://mygainwell.sharepoint.com.mcas.ms/teams/ClinicalLibrary/PublicClinicalDocuments/Forms/AllItems.aspx?id=%2Fteams%2FClinicalLibrary%2FPublicClinicalDocuments%2FInpefa%20%28sotagliflozin%29%2Epdf&parent=%2Fteams%2FClinicalLibrary%2FPublicClinicalDocuments){:target="_blank" rel="noopener"}

| **WAC Price per Unit and Cost per Year/Treatment** |
| --------|
| Inpefa 200 mg tablet 30-day supply: $598.00 or $7,176.00 annually |

| **Suggested Prior Authorization/Utilization Management Criteria** |
| --------|
| ***Approval length***: Initial- 6 months; Continuation of therapy- 1 year |
| ***Indication***: Reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure OR type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors. |
| ***Initial Therapy***: <li>Age 18 years and older</li><li>Diagnosis of heart failure OR type 2 diabetes and chronic kidney disease</li><li>Trial/failure and/or contraindication to both Jardiance and Farxiga</li><li>Use with standard of care for associated disease states (e.g., ACE inhibitors, ARBs, beta-blockers, loop-diuretics)</li> |
| ***Continuation of Therapy***: <li>  Provider documentation of continued benefit </li> |
| ***Additional Considerations***: <li>Pregnancy: Advise females of the potential risk to a fetus especially during the second and third trimesters. </li><li>Lactation: Inpefa is not recommended when breastfeeding.</li> | 

## Qalsody (tofersen) 5/9/23

[Qalsody (tofersen).pdf](https://mygainwell.sharepoint.com.mcas.ms/teams/ClinicalLibrary/PublicClinicalDocuments/Forms/AllItems.aspx?id=%2Fteams%2FClinicalLibrary%2FPublicClinicalDocuments%2FQalsody%20%28tofersen%29%2Epdf&parent=%2Fteams%2FClinicalLibrary%2FPublicClinicalDocuments){:target="_blank" rel="noopener"}

| **WAC Price per Unit and Cost per Year/Treatment** |
| --------|
| $14,230/15 mL vial. Annual WAC price (initial dose plus maintenance doses): $199,219. |

| **Suggested Prior Authorization/Utilization Management Criteria** |
| --------|
| ***Approval length***: Initial- 6 months; Continuation of therapy- 1 year |
| ***Indication***: Treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. This indication is approved under accelerated approval based on reduction in plasma neurofilament light (NfL) chain observed in patients treated with Qalsody. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s). |
| ***Initial Therapy***: <li>Therapy is prescribed by or in consultation with a neurologist or ALS specialist</li><li>Diagnosis of ALS with weakness attributable to ALS and a SOD1 mutation confirmed by a central laboratory</li><li>Age ≥18 years</li><li>Documentation of baseline disease functioning including at least one of the following: ALSFRS-R score, plasma NfL, percentage of the predicted slow vital capacity (SVC), the handheld dynamometry megascore</li> |
| ***Continuation of Therapy***: <li>Patient remains independent of tracheostomy</li><li>Provider attests to likelihood of continued patient benefit with longer course of therapy </li><li>Provider attests to continued monitoring of plasma NfL </li> |

## Joenja (leniolisib) 5/2/23

[Joenja (leniolisib).pdf](https://mygainwell.sharepoint.com.mcas.ms/teams/ClinicalLibrary/PublicClinicalDocuments/Forms/AllItems.aspx?id=%2Fteams%2FClinicalLibrary%2FPublicClinicalDocuments%2FJoenja%20%28leniolisib%29%2Epdf&parent=%2Fteams%2FClinicalLibrary%2FPublicClinicalDocuments){:target="_blank" rel="noopener"}

| **WAC Price per Unit and Cost per Year/Treatment** |
| --------|
| Each 70 mg tablet: $750.00. Dosed twice daily, Joenja has an annual cost of: $547,500.00  |

| **Suggested Prior Authorization/Utilization Management Criteria** |
| --------|
| ***Approval length***: Initial- 6 months; Continuation of therapy- 1 year |
| ***Indication***: Treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older |
| ***Initial Therapy***: <li>Patient aged 12- 75 years of age AND</li><li>Documented APDS/PASLI associated PIK3CD/PIK3RI mutation AND</li><li>Patient not on concurrent immunosuppressive medication. Prior immunosuppressive therapy must be discontinued within 6 weeks of treatment initiation AND</li><li>Documented evidence of nodal and/or extranodal lymphoproliferation AND</li><li>Documented evidence of oto-sino-pulmonary infections OR organ dysfunction AND</li> <li>Documented negative pregnancy test for females of childbearing potential</li> |
| ***Continuation of Therapy***: <li>Documented clinical response in signs and manifestations of APDS or clinical stabilization (i.e., naive B cell improvement and/or lymph node size reduction) </li><li>Documented negative pregnancy test for females of childbearing potential</li> |


## Skyclarys (omaveloxolone) 3/30/23

[Skyclarys (omaveloxolone).pdf](https://mygainwell.sharepoint.com.mcas.ms/teams/ClinicalLibrary/PublicClinicalDocuments/Forms/AllItems.aspx?id=%2Fteams%2FClinicalLibrary%2FPublicClinicalDocuments%2FSkyclarys%20%28omaveloxolone%29%2Epdf&parent=%2Fteams%2FClinicalLibrary%2FPublicClinicalDocuments){:target="_blank" rel="noopener"}

| **WAC Price per Unit and Cost per Year/Treatment** |
| --------|
| Based on a WAC of $342.59 per 50-mg capsule and a daily dose of 150 mg, the annual WAC of Skyclarys is $375,136.  |

| **Suggested Prior Authorization/Utilization Management Criteria** |
| --------|
| ***Approval length***: Initial- 6 months; Continuation of therapy- 1 year |
| ***Indication***: Friedreich ataxia (FA) in adults and adolescents aged 16 years and older |
| ***Initial Therapy***: <li> Genetically confirmed diagnosis of FA (testing options include a single gene test looking for GAA expansions in intron 1 of the FXN gene or a multigene panel)</li><li>Prescribed by or in consultation with a neurologist</li><li>Patient is aged 16 to 40 years</li><li>Patient is ambulatory</li> |
| ***Continuation of Therapy***: <li>Documentation of clinically significant improvement and/or stabilization in clinical signs and symptoms of disease (including but not limited to upright stability, performing ADL, improved gait)</li> |

## Daybue (trofinetide) 4/4/23

[Daybue (trofinetide).pdf](https://mygainwell.sharepoint.com.mcas.ms/teams/ClinicalLibrary/PublicClinicalDocuments/Forms/AllItems.aspx?id=%2Fteams%2FClinicalLibrary%2FPublicClinicalDocuments%2FDaybue%20%28trofinetide%29%2Epdf&parent=%2Fteams%2FClinicalLibrary%2FPublicClinicalDocuments){:target="_blank" rel="noopener"}

| **WAC Price per Unit and Cost per Year/Treatment** |
| --------|
| $76,000/ mo (≥ 50 kg patient) or $912,000 annually ($228,000 for 12-week treatment)  |

| **Suggested Prior Authorization/Utilization Management Criteria** |
| --------|
| ***Approval length***: Initial- 12 weeks; Continuation of therapy- 1 year |
| ***Indication***: Treatment of Rett syndrome in adults and pediatric patients 2 years of age and older |
| ***Initial Therapy***: <li> Prescribed by or in consultation with a neurologist or specialist AND</li><li>Patient age ≥2 years AND</li><li>Patient weight ≥9 kg AND</li><li>Diagnosis of Rett Syndrome with the following documented: <ol><li>RTT Clinical Severity Scale rating of 10–36 </li><li>Clinical Global Impression-Severity score of ≥4 AND</li></ol><li> Documentation of MEPC2 genetic mutation</li> |
| ***Continuation of Therapy***: <li>Documentation of improvement in RTT Clinical Severity Scale from baseline</li><li>Documentation of improvement in CGI score (score continues ≥4) from baseline</li> |

## Filspari (sparsentan) 3/14/23

[Filspari (sparsentan) pdf](https://mygainwell-my.sharepoint.com/:b:/g/personal/christopher_nguyen_gainwelltechnologies_com/EfU8u4e7XeJCnMYNLTE10TQBIcJuzWO6Ky1pwxU6GnCTXA?e=qeHm2G){:target="_blank" rel="noopener"}

| **WAC Price per Unit and Cost per Year/Treatment** |
| --------|
| 1 tablet/ 30 days (for both 200 mg and 400mg) $9,900/ month or $118,000 annually  |

| **Suggested Prior Authorization/Utilization Management Criteria** |
| --------|
| ***Approval length***: Initial- 6 months; Continuation of therapy- 6 months |
| ***Indication***: Reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g |
| ***Initial Therapy***: <li> Prescribed by or in consultation with a nephrologist or a related specialist AND</li><li>Diagnosis of IgAN as confirmed by biopsy AND</li><li>Evidence of proteinuria ≥1 g/day and eGFR ≥ 30 mL/ min AND</li><li>Trial and failure of an ACE Inhibitor or ARB (90/120 days w/ UPCR ≥1 g/day) or documented contraindication/intolerance to therapy</li> |
| ***Continuation of Therapy***: <li>Documentation of UPCR ≤ 1 g/day</li><li>eGFR ≥ 30 mL/ mine</li> |
| ***Additional Considerations***: <li>Filspari is only available through a **REMS program** which requires pregnancy testing before, during, and after treatment.</li><li>Patients who can become pregnant must use effective contraception prior to initiation of treatment, during treatment, and for one month after discontinuation of treatment.</li><li>Measure liver aminotransferases and total bilirubin prior to initiation of treatment and ALT and AST monthly for 12 months, then every 3 months during treatment.</li><li>Prior to initiating treatment with Filspari, discontinue use of renin-angiotensin-aldosterone system (RAAS) inhibitors, endothelin receptor antagonists (ERAs), or aliskiren.</li> | 

## Leqembi (lecanemab-irmb) 1/24/23

[Leqembi (lecanemab-irmb) pdf](https://mygainwell-my.sharepoint.com/:b:/g/personal/christopher_nguyen_gainwelltechnologies_com/EQCFNZJ9zG9OiK4zmDf-NyoBF189Qg3sDggfIzi-t17BkA?e=GdbZ77){:target="_blank" rel="noopener"}

| **WAC Price per Unit and Cost per Year/Treatment** |
| --------|
| Annual WAC price estimated for 70 kg patient (dosed 10 mg/kg every two weeks) is $23,184.00.  |

| **Suggested Prior Authorization/Utilization Management Criteria** |
| --------|
| ***Approval length***: Initial- 6 months; Continuation of therapy- 6 months |
| ***Indication***: Treatment of Alzheimer’s disease (AD). Treatment with Leqembi should be initiated in patients with mild cognitive impairment (MCI) or mild dementia stage of disease. There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied. Confirm the presence of amyloid beta pathology prior to initiating treatment. |
| ***Initial Therapy***: <li>Age 50 years or older AND</li><li>Prescribed by or in consultation with a neurologist, geriatrician, or other specialist in the treated disease state AND</li><li>Documentation of mild dementia or mild cognitive impairment associated with Alzheimer’s disease via MMSE, CDR-SB or ADAS-Cog 14 score AND </li><li>Documentation of positive amyloid beta pathology on recent PET scan AND</li> <li>Documentation of recent brain MRI (within one year) to evaluate for pre-existing Amyloid 
Related Imaging Abnormalities (ARIA) AND</li><li>Patient must not be prescribed anticoagulant medications</li> |
| ***Continuation of Therapy***: <li>Documentation of follow-up MRIs to evaluate for ARIA-E, ARIA-H, and other structural changes prior to the 5th, 7th, and 14th infusions, then at least once annually AND</li><li>Documentation of current disease severity as demonstrated by current MMSE score, CDR-SB or ADAS-COG score</li> |
| ***Additional Considerations***: <li>If radiographically observed ARIA occurs, treatment recommendations are based on type, severity, and presence of symptoms</li><li>Consider testing for ApoE ε4 status to inform the risk of developing ARIA when deciding to initiate treatment with Leqembi</li><li>Evaluate patients for evidence of established cardiovascular disease and discuss increased risk of ARIA and complications with Leqembi use in those with positive histories</li><li>Because intracerebral hemorrhages greater than 1 cm in diameter have been observed in patients taking Leqembi, additional caution should be exercised when considering the administration of antithrombotics or a thrombolytic agent (e.g., tissue plasminogen activator) to a patient already being treated with Leqembi</li><li>Discontinue Leqembi when patient has progressed to moderate AD</li>| 

## Hemgenix® (etranacogene dezaparvovec-drlb) 1/3/23

[***Carve Out Medication Process]([https://special-spoon-f542dccd.pages.github.io/Pharmacist%20Reference%20Guide/Clinical%20and%20PA%20Notes/newdrugreview/](https://special-spoon-f542dccd.pages.github.io/Clinical%20and%20Technical%20Reference%20Guide/PA%20-%20Standard%20of%20Work/carved_out_medications/?h=carve)https://special-spoon-f542dccd.pages.github.io/Clinical%20and%20Technical%20Reference%20Guide/PA%20-%20Standard%20of%20Work/carved_out_medications/?h=carve)

[Hemgenix® (etranacogene dezaparvovec-drlb) pdf](https://mygainwell-my.sharepoint.com/:b:/g/personal/christopher_nguyen_gainwelltechnologies_com/EeakbsctyOpIjgZqJWWVaTMBZIPQmipBFioOeFGF1lxyvw?e=miP1Pg){:target="_blank" rel="noopener"}

| **WAC Price per Unit and Cost per Year/Treatment** |
| --------|
| $3.5 million for a one-time infusion  |

| ~~**Suggested Prior Authorization/Utilization Management Criteria**~~ |
| --------|
| ~~***Approval length***: 3 months, one infusion per lifetime~~  |
| ~~***Indication***: Treatment of hemophilia B (congenital factor IX [FIX] deficiency) in adults with:<li>Current or history of life-threatening hemorrhage, OR</li> <li>Repeated, serious spontaneous bleeding episodes, OR </li><li>Current use of FIX prophylaxis therapy</li>~~ |
| ~~***Quantity limit***: 2 x 10 genome copies per kg of body weight~~ |
| ~~***Initial Therapy***: <li>Prescribed by, or in consultation with, a hematologist</li><li>Male gender assigned at birth and aged >18 years</li><li>Documented diagnosis of hemophilia B based on a factor assay to demonstrate deficiency of FIX AND<ul><li>Documentation of moderate disease (FIX level 1-5IU/dL, or 1%-5% of normal) OR</li><li>Documentation of severe disease (FIX level <1 IU/dL, or <1% of normal)</li></ul><li>Current use of FIX prophylaxis for > 2 months with greater than 150 previous exposure days of treatment with FIX protein OR<ul><li>Have current or historical life-threatening hemorrhage OR</li><li>Have repeated, serious spontaneous bleeding episodes</li></ul><li>Delivery of gene therapy with Hemgenix is done by or in consultation with a HTC</li>~~ |
| ~~***Hemgenix will NOT be covered when ANY the following are present:***: <li>History of FIX inhibitors or a positive inhibitor screen conducted within the past 12 months (confirmed as 0.6 BU/mL [Bethesda Unit] or greater by chromogenic Bethesda Assay or other immunologic test)</li><li>Documentation of current disease severity as demonstrated by current MMSE score, CDR-SB or ADAS-COG score</li><li>Previous gene therapy treatment</li><li>Active hepatitis B infection, hepatitis C infection, or uncontrolled HIV infection</li><li>History of hepatitis B or C exposure currently controlled by antiviral therapy</li><li>Evidence of advanced liver fibrosis (screening laboratory values [i.e., ALT, AST, bilirubin, ALP, creatinine] > 2 times upper limits of normal)</li>~~ | 

## Skysona (elivaldogene autotemcel) 10/18/22

[***Carve Out Medication Process]([https://special-spoon-f542dccd.pages.github.io/Pharmacist%20Reference%20Guide/Clinical%20and%20PA%20Notes/newdrugreview/](https://special-spoon-f542dccd.pages.github.io/Clinical%20and%20Technical%20Reference%20Guide/PA%20-%20Standard%20of%20Work/carved_out_medications/?h=carve)https://special-spoon-f542dccd.pages.github.io/Clinical%20and%20Technical%20Reference%20Guide/PA%20-%20Standard%20of%20Work/carved_out_medications/?h=carve)

[Skysona (elivaldogene autotemcel) pdf](https://mygainwell-my.sharepoint.com/:b:/g/personal/christopher_nguyen_gainwelltechnologies_com/EdaApYYb-xpNizwiriI6AtsBltzVMGwM33fSzLpKm_uCOw?e=BiPp0Y){:target="_blank" rel="noopener"}

| **WAC Price per Unit and Cost per Year/Treatment** |
| --------|
| $3,000,000 WAC price for one-time treatment (this does not include associated costs with administration) |

| ~~**Suggested Prior Authorization/Utilization Management Criteria**~~ |
| --------|
| ~~***Approval length***: one-time authorization~~  |
| ~~***Indication***: Slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). Early, active CALD refers to asymptomatic or mildly symptomatic (neurologic function score, NFS ≤ 1) boys who have gadolinium enhancement on brain magnetic resonance imaging (MRI) and Loes scores of 0.5-9~~  |
| ~~***Initial Therapy***: <li>PPrescribed by or in consultation with a neurologist, endocrinologist, hematologist and/or oncologist AND</li><li>Patient aged 4 -17 years AND</li><li>CALD diagnosis (E71.520, Childhood cerebral X-linked adrenoleukodystrophy; E71.521, Adolescent X-linked adrenoleukodystrophy) confirmed by genetic testing (ABCD1 gene mutation) AND<li>Candidate for HSCT, but does NOT have access to matched donor AND patient has not received prior HSCT for CALD AND</li><li> Evidence of early active CALD defined by **ALL** of the following: <ul><li>Elevated VLCFA values </li><li>Loes score between 0.5 and 9</li><li>GdE+ on MRI of demyelinating lesions </li><li>NFS≤1 </li></ul>~~ |
| ~~***Additional Considerations***: <li>Perform screening for hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus 1 & 2 (HIV-1/HIV-2) and Human T-lymphotropic virus 1 & 2 (HTLV-1/HTLV-2) in accordance with clinical guidelines before collection of cells for manufacturing.</li>~~ | 

## Zynteglo (betibeglogene autotemcel) 9/9/22

[***Carve Out Medication Process]([https://special-spoon-f542dccd.pages.github.io/Pharmacist%20Reference%20Guide/Clinical%20and%20PA%20Notes/newdrugreview/](https://special-spoon-f542dccd.pages.github.io/Clinical%20and%20Technical%20Reference%20Guide/PA%20-%20Standard%20of%20Work/carved_out_medications/?h=carve)https://special-spoon-f542dccd.pages.github.io/Clinical%20and%20Technical%20Reference%20Guide/PA%20-%20Standard%20of%20Work/carved_out_medications/?h=carve)

[Zynteglo (betibeglogene autotemcel) pdf](https://mygainwell-my.sharepoint.com/:b:/g/personal/christopher_nguyen_gainwelltechnologies_com/EddvDWZeo0tIo8SAlJmQX88BXk8sqo3koRdl37HbCm4mmA?e=77hqEe){:target="_blank" rel="noopener"}

| **WAC Price per Unit and Cost per Year/Treatment** |
| --------|
| $2.8 million for one-time treatment |

| ~~**Suggested Prior Authorization/Utilization Management Criteria**~~ |
| --------|
| ~~***Approval length***: one-time authorization~~  |
| ~~***Indication***: Treatment of beta-thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions~~ |
| ~~***Initial Therapy***: <li>Patient is aged ≥4 years AND</li><li>Prescribed by or in consultation with a hematologist, oncologist, or other specialist in the disease state AND</li><li>Diagnosis of TDT evidenced by severe non-β0/β0 or β0/β0 genotype AND</li><li>History of >100 mL/kg/year of packed RBCs OR >8 RBC transfusions per year within the past 2 years AND</li><li>Patient is a candidate for HSCT, but does NOT have access to matched donor AND</li><li>Patient has not had a previous HSCT procedure AND</li><li>Patient is clinically stable and does not have evidence of severe iron overload or serious comorbidities that would preclude myeloablative chemotherapy</li>~~ |

## Rebyota (fecal microbiota, live-jslm) 1/6/23

[Rebyota (fecal microbiota, live-jslm) rectal suspension pdf](https://mygainwell-my.sharepoint.com/:b:/g/personal/christopher_nguyen_gainwelltechnologies_com/Eb9mQPWKOz9IssHErYkB1NIBw5sBvtmpBcrd8Lm_eNbfTw?e=dFHW9b){:target="_blank" rel="noopener"}

| **WAC Price per Unit and Cost per Year/Treatment** |
| --------|
| $9,000/one-time dose |

| **Suggested Prior Authorization/Utilization Management Criteria** |
| --------|
| ***Approval length***: one-time   |
| ***Indication***: For the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older, following antibiotic treatment for recurrent CDI (rCDI) |
| ***Initial Therapy***: <li>One of the following:</li><ul><li>Prescribed by or in consultation with a gastroenterologist or infectious disease provider OR</li><li>Both of the following: </li><ol><li>Positive stool test for the presence of Clostridioides difficile within previous 30 days **AND**</li><li>Patient is not currently taking an inciting antibiotic (e.g., amoxicillin, 3rd generation cephalosporins, clindamycin, fluoroquinolones)</li></ol></ul><li>Second recurrence (i.e., third episode) or greater of C. difficile infection (CDI) AND</li><li>Patient is ≥ 18 years of age4 AND</li><li>For adults, patient has been previously treated with either vancomycin and/or Dificid (fidaxomicin)</li> |
| ***Continuation of Therapy***: <li>Not approvable</li> |

## Tzield (teplizumab-mzwv) 12/13/22

[Tzield (teplizumab-mzwv) pdf](https://mygainwell-my.sharepoint.com/:b:/g/personal/christopher_nguyen_gainwelltechnologies_com/EQxQbRq0F9dCsJFIyJKVwhoB7AcsUtyATJbtKa3oWbZY7w?e=sjc0I8){:target="_blank" rel="noopener"}

[** See Clinical Team Suggestion](https://special-spoon-f542dccd.pages.github.io/Pharmacist%20Reference%20Guide/Clinical%20and%20PA%20Notes/Tzield/?h=tz)

| **WAC Price per Unit and Cost per Year/Treatment** |
| --------|
| $6,925.00 per mL; WAC for one 14-day course of therapy with Tzield is estimated at $193,900 using the BSA of a typical 13-year-old (1.33 m2). |

| **Suggested Prior Authorization/Utilization Management Criteria** |
| --------|
| ***Approval length***:  1-time therapy (14 days)   |
| ***Indication***: To delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D  |
| ***Initial Therapy***: <li>Prescribed by or in consultation with an endocrinologist AND</li><li>Patient aged 8 years of age and older AND</li><li>Diagnosis of Stage 2 T1D by documentation of **ALL the following**:</li><ul><li>Presence of ≥ 2 autoantibodies (e.g., GAD65, IAA, IA-2A, ICA, or ZnT8) </li><li>Evidence of dysglycemia (e.g., fasting glucose (FG) level of 110 to 125 mg/dL (6.1 to 6.9 mmol/L), a 2-hour postprandial plasma glucose level of at least 140 mg/dL (7.8 mmol/L) and less than 200 mg/dL (11.1 mmol/L))</li></ul> |
| ***Tzield will NOT be administered if any of the following is present***:<li>Active and/or chronic infection</li><li>Severe lymphopenia (<500 cells per mcL) noted on baseline laboratory assessment</li><li>Elevated LFTs on baseline laboratory assessment</li><li>Diagnosis of T2D</li><li>Diagnosis of Stage 3 T1D </li> |
| ***Additional Considerations***: <li>Prior to initiating Tzield, obtain a complete blood count and liver enzyme tests. Use of Tzield is not recommended in patients with certain laboratory abnormalities (i.e., 3x upper limit of normal ALT and/or AST)</li><li>Administer all age-appropriate vaccinations prior to starting Tzield</li><li>Duration of approval should not exceed 3 months to prevent patients receiving Tzield after progressing to Stage 3 TID due to lapse between approval and administration of drug. </li> |

## Relyvrio (sodium phenylbutyrate and taurursodiol) 11/1/22

[Relyvrio (sodium phenylbutyrate and taurursodiol) pdf](https://mygainwell-my.sharepoint.com/:b:/g/personal/christopher_nguyen_gainwelltechnologies_com/ESYcwoUtr4pGo4iKE2bUAx0BREesFmhv4-xp--a9DReY6A?e=gUDJ28){:target="_blank" rel="noopener"}

| **WAC Price per Unit and Cost per Year/Treatment** |
| --------|
| Annual WAC price of $158,313.00 for first year of treatment |


| **Suggested Prior Authorization/Utilization Management Criteria** |
| --------|
| ***Approval length***:  Initial- 6 months; Continuation of therapy- 1 year  |
| ***Indication***: Treatment of amyotrophic lateral sclerosis (ALS) in adults  |
| ***Initial Therapy***: <li>Therapy is prescribed by or in consultation with a neurologist or ALS specialist</li><li>Diagnosis of ALS and within 18 months of symptom onset </li><li>SVC >60%</li><li>Age ≥18 years</li><li>Patient does not have a tracheostomy</li> |
| ***Continuation of Therapy***: <li>Patient remains independent of tracheostomy</li><li>Provider attests to likelihood of continued patient benefit with longer course of therapy</li> |

## Xenpozyme ® (Olipudase Alfa-rpcp) 10/11/22

[Xenpozyme ® (Olipudase Alfa-rpcp) pdf](https://mygainwell-my.sharepoint.com/:b:/g/personal/christopher_nguyen_gainwelltechnologies_com/EaYsH8Ukwu5PlwfB7lmhSS0B_wb3oW6fY7TixhSAqZkLwg?e=u3PAUe){:target="_blank" rel="noopener"}

| **WAC Price per Unit and Cost per Year/Treatment** |
| --------|
| The wholesale acquisition cost (WAC) of Xenpozyme is $7,142 per vial <li>The estimated monthly cost of Xenpozyme is $157,124 with an annual cost exceeding $2 million (based on the maximum recommended target dose for a 70kg adult). These estimates do not include administration or facility fees that may be added</li> |


| **Suggested Prior Authorization/Utilization Management Criteria** |
| --------|
| ***Approval length***: Initial- 6 months; Continuation of therapy- 1 year  |
| ***Indication***: Treatment of non-central nervous system (CNS) manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients with ASMD Type A/B or ASMD Type B  |
| ***Quantity Limit***: 3 mg/kg every 2 weeks |
| ^^Pretreatment Recommendations^^: <li>Obtain baseline transaminase alanine aminotransferase [ALT] and aspartate aminotransferase [AST] levels within 1 month prior to treatment initiation</li><li>Verify pregnancy status in females of reproductive potential</li><li>Consider pretreating with antihistamines, antipyretics, and/or corticosteroids</li> |
| ***Initial Therapy***: <li>Prescribed by, or in consultation with, a specialist in a related field (i.e., hematology, hepatology, pulmonology, medical geneticist, or metabolic disease specialist); AND</li><li>Patient has a documented diagnosis of ASMD; AND</li><li>Patient has a clinical presentation consistent with ASMD type A/B OR ASMD type B; AND</li><li>Diagnosis has been confirmed by documentation of at least one of the following:<ul><li>Sphingomyelin phosphodiesterase-1 (SMPD1) gene mutation; OR</li><li>Deficiency in ASM activity measured in fibroblasts, leukocytes, or dried blood spot; AND</li></ul><li>Patient is using for the treatment of non-CNS disease manifestations including at least one of the following: splenomegaly (confirmed as a spleen volume >6 multiples of normal [MN] in adults or >5 MN in children), hepatomegaly, pulmonary dysfunction (confirmed by a DLco <70%), or thrombocytopenia.</li> |
| **Patient does not have**: <li>Acute or rapidly progressive neurologic abnormalities</li><li>A requirement for use of invasive ventilatory support or noninvasive ventilatory support while awake and for greater than 12 hours a day</li><li>A platelet count of <60 x 103/microliter</li><li>International normalized ratio (INR) > 1.5</li><li>ALT or AST >250 IU/L or bilirubin > 1.5mg/dL</li> |
| ***Continuation of Therapy***: <li>Documented positive clinical response to therapy, or stabilization in signs and symptoms of disease, including a baseline comparison showing improvement in at least one of the following: DLco test, platelet count, spleen and liver volumes.</li> |
